NEUROLOGY PODCAST

"The Neurology Podcast” es un programa desarrollado por la revista Neurology y la American Academy of Neurology, que proporciona información práctica para neurólogos que les ayudará en su práctica clínica y mejorará la atención al paciente. Cada semana los oyentes pueden ganar créditos CME completando cuestionarios en línea en neurology.org

Neurology® Podcast January 2023 Neurology Recall: Autoimmune Neurologic Disorders

The January 2023 replay of past episodes showcases a selection of interviews covering a variety of topics in Autoimmune Neurologic Disorders. This episode features conversations with Dr. Marinos Dalakas on IVIg efficacy in GAD65 positive SPS patients , followed by an interview with Prof. Bart Jacobs about the association of preceding infections with the clinical variation of Guillain-Barré syndrome across geographical regions, leading into an interview with Prof. Sarosh Irani on the use of corticosteroids as a first-line agent in the treatment of LGI1-antibody encephalitis. January’s Neurology Recall concludes with an interview with Dr. Ming Lim on the diagnosis and management of Opsoclonus Myoclonus Ataxia Syndrome (OMAS) in children.

 

Associated Articles: 

Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome | Neurology Neuroimmunology & Neuroinflammation

An International Perspective on Preceding Infections in Guillain-Barré Syndrome | Neurology 

Improving clinical practice with an old friend from the neuroimmunology toolkit: acute corticosteroids in LGI1 antibody encephalitis | Journal of Neurology, Neurosurgery & Psychiatry (bmj.com)

Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children | Neurology Neuroimmunology & Neuroinflammation

Disclosures can be found at Neurology.org.

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

Este sitio usa Akismet para reducir el spam. Aprende cómo se procesan los datos de tus comentarios.